<DOC>
	<DOCNO>NCT01063647</DOCNO>
	<brief_summary>Evaluation safety efficacy 3 x 10 , 3 x 12 3 x 14 g/m² Treosulfan resp. , combine 5 x 30 mg/m² fludarabine prior allogeneic , hematopoietic stem cell transplantation patient hematological malignancy , non-eligible standard conditioning treatment .</brief_summary>
	<brief_title>Dose-range Finding Treosulfan-based Conditioning</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Patients haematological chemosensitive malignancy indicate allogeneic transplantation , present increase toxicity risk classical ( highdose busulfan standarddose total body irradiation ) conditioning therapy ( remission criterion ref . Appendix L ) : CML first subsequent chronic phase NHL 2nd CR/PR , chemosensitive PR autologous transplantation ; CLL 2nd subsequent CR/PR Relapsed Morbus Hodgkin ( MH ) autologous transplantation Multiple Myeloma ( MM ) stage II III accord Durie Salmon AML 2nd CR/PR highrisk AML 1st CR/PR Highrisk define example following : Cytogenetics : 5/5q , 7/7q , del ( 5q ) , abnormalities 3q , complex karyotype ( &gt; 3 abnormality ) , PR 1 cycle induction therapy ALL 2nd CR/PR highrisk ALL 1st CR/PR Highrisk define follow : Leukocytes &gt; 3000/µl ( BLinage ) &gt; 100000/µl ( TLinage ) ; ProBALL , preTALL Cytogenetics : ( 9 ; 22 ) /BCRABL ; ( 4 ; 11 ) /ALL1AF MDS ( patient without prior chemotherapy may include ) 2 . Availability HLAidentical sibling donor ( MRD ) HLAidentical unrelated donor ( MUD ) one mismatch ( 6 standard marker ) sibling donor ( 1 misMRD ) : • HLAidentity define follow marker : A , B , DRB1 . DQB1 must record . 3 . Age &gt; 18 year 4 . Karnofsky Index &gt; 80 % 5 . Adequate contraception female patient childbearing potential 6 . Cooperative behavior individual patient 7 . Written inform consent 1 . Completely chemotherapyresistant disease 2 . Severe cardiac insufficiency , severe cardiovascular severe concomitant diseases 3 . Symptomatic malignant involvement CNS 4 . Active infectious disease 5 . HIVpositive active hepatitis infection 6 . Impaired liver function ( Bilirubin &gt; 1.5 x upper normal limit ; Transaminases &gt; 3.0 x upper normal limit ) 7 . Impaired renal function ( Creatinineclearance &lt; 60 ml/min ; Serum Creatinine &gt; 1.5 x upper normal limit ) . 8 . Pleural effusion ascites &gt; 1.0 L 9 . Pregnancy lactation 10 . Known hypersensitivity fludarabine and/or treosulfan 11 . Parallel participation another experimental drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Treosulfan</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>Conditioning therapy</keyword>
</DOC>